There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.
TREATMENT OF CORNEAL NEOVASCULARIZATION
申请人:IRBM SCIENCE PARK S.p.A.
公开号:US20180021327A1
公开(公告)日:2018-01-25
There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.
NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN
申请人:OSPEDALE SAN RAFFAELE S.R.L.
公开号:US20210015834A1
公开(公告)日:2021-01-21
The invention relates to compounds, in particular NK-1 antagonists, for use in the treatment of ocular sensitivity and/or ocular pain.